Olimel

The Olimel portfolio gives you the broadest selection of three-chamber bags with an olive oil-based lipid to meet the unique nutrition needs of each patient.

Vedi indicazioni Contatti
Olimel 3CB

Not all critically ill patients are the same, and neither are their nutritional requirements. The Olimel portfolio offers a range of central and peripheral formulations to match the individual protein and energy needs of your patients.1-3  Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, three-chamber bag (3CB).2,3,18-23  Olimel contains olive oil, which is rich in long-chain Omega-9 monounsaturated fatty acids (MUFAs), with fewer polyunsaturated fatty acids (PUFAs) than soybean and fish oil.26 An olive oil-based lipid emulsion may preserve immune function and has been associated with fewer infections than soybean oil.4,10-12

See full prescribing information for Olimel N12 SmPC
See full prescribing information for Olimel N12E SmPC
See full prescribing information for PeriOlimel N4 & Olimel N5, N7, N9 SmPC

Patient and doctor in hospital

Meeting protein targets is key to hospitalized patients’ recovery

During recovery, hospitalized patients face two serious challenges. Firstly, they may be immunocomprimised which can lead to severe complications.5 Secondly, catabolic stress from acute infection, trauma or severe tissue injury depletes protein stores in the skeletal muscle which can lead to poor wound healing, muscle weakness, prolonged ventilator time, and extended hospital stay.6-8 Proper protein intake with parenteral nutrition (PN) not only ensures sufficient caloric intake but also an essential nutrient balance. Still, most critically ill patients receive only half the recommended protein intake during their first weeks in the intensive care unit (ICU).9   

Olimel - meeting the unique nutritional needs of each patient

Preserve immune function icon

Preserve immune function

Olimel contains an olive oil-based lipid emulsion, which is associated with fewer infections and may preserve immune function.4,10-12

Reach protein targets  with less fluid icon

Reach protein targets with less fluid

Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized 3CB.2,3,18-23

Personalize without compromise icon

Personalize without compromise

Broadest selection of 3CBs to meet the unique nutrition needs of each patient.1-3

Reduce risk of hyperglycemia icon

Reduce risk of hyperglycemia

Hyperglycemia is associated with an increased risk of infections.15-19 With only 73 g/L, Olimel N12 has one of the lowest glucose levels available in a 3CB.2,3,18-23

Learn about the importance of protein in PN

Dr. Paul Wischmeyer explains the power of protein. Olimel was not administered in these studies.

The power of protein

When compared to standard intake, higher protein as prescribed by guidelines was associated with significant clinical improvements in ICU patients.24 A higher and earlier intake of protein has proven to be beneficial in wound healing, hormonal regulation, and cell signaling and was significantly associated with lower mortality as illustrated by a one percent reduction in mortality for every gram of daily protein ingested.7,25

Association of protein intake with 60-day mortality25

Graph adapted from Zusman O, et al. Crit Care 2016;20;367-374(39) showing that the results from the study suggests a  1% reduction in mortality for every 1 gram of daily protein ingested.
Graph adapted from Zusman O, et al. Crit Care 2016;20;367-374(39) showing that the results from the study suggests a 1% reduction in mortality for every 1 gram of daily protein ingested.

Browse the Olimel portfolio

Olimel N12 composition

Olimel N12

For patients with high catabolic stress 

Olimel N12 is Baxter’s latest generation of industry-leading PN 3CBs and combines a high protein formulation with low glucose content.2,3  Olimel N12 also contains an olive oil-based lipid emulsion which is supported by more than 20 years of proven clinical evidence.  

Olimel N12 is formulated for PN in patients with the highest protein demand, or patients who are at risk of overfeeding or fluid overload. Olimel N12 without electrolytes can be administered to provide protein, fatty acids and calories to non-acutely ill malnourished patients receiving intradialytic PN (IDPN).

See full prescribing information for Olimel N12 SmPC

See full prescribing information for Olimel N12E SmPC

Olimel N9 composition

Olimel N9

For patients with moderate catabolic stress 

Olimel N9 is formulated for PN in moderate stress patients with high protein and moderate energy demands. Olimel N9 without electrolytes can be administered to provide protein, fatty acids and calories to non-acutely ill malnourished patients receiving IDPN. 

See full prescribing information
Olimel N7 composition

Olimel N7

For patients with moderate catabolic stress 

Olimel N7 is formulated for PN in moderate stress patients in stable conditions with moderate protein and higher energy demands. 

See full prescribing information
Olimel N5 composition

Olimel N5

For patients with low catabolic stress

Olimel N5 is formulated for PN in low stress patients in stable conditions with moderate protein and higher energy demands. 

See full prescribing information
PeriOlimel N4 composition

PeriOlimel N4

For patients with low catabolic stress 

PeriOlimel N4 is formulated for PN in stable patients that need a conveniently delivered, short-term nutrition solution.  PeriOlimel N4 is specifically formulated for peripheral delivery. 

See full prescribing information

How to activate an Olimel bag

How to activate an Olimel bag visual

1. Peel the overpouch

Peel the front of overpouch using the notches. Discard the overpouch. Confirm the integrity of the bag and nonpermanent seals. Use only if the bag is not damaged and the nonpermanent seals are intact.

2. Roll the bag

Place the bag flat and manually roll the bag onto itself, starting at the top of the bag (hanger end). Continue to roll the bag until the seals are opened along approximately half of their length.

3. Mix the content 

Mix by inverting the bag at least 3 times. After reconstitution, the mixture is a homogeneous emulsion with a milky appearance.

4. Add micronutrients and other additions (if needed)

The capacity of the bag is sufficient to enable additions such as vitamins, electrolytes, and trace elements. Also, vitamins may be added into the glucose compartment before the mixture is reconstituted. Any further additions may be made into the reconstituted mixture. After any additions are made, mix the contents of the bag and the additives.

To perform an addition:
- Aseptic conditions must be observed.
- Prepare the injection site of the bag.
- Puncture the injection site and inject the additives using an injection needle or a reconstitution device.
- Mix content of the bag and the additives.

Compatibility may vary between products from different sources and health care professionals are advised to carry out appropriate checks when mixing Olimel with other parenteral solutions.

5. Administer PeriOlimel/Olimel
Aseptic conditions must be observed. Remove the plastic protector. Twist off the protector from the administration outlet and firmly insert the spike of the infusion set into the administration outlet. The recommended duration of infusion is between 12 and 24 hours.

Learn more about Clinical Nutrition

Doctors talking

Visit the Clinical Nutrition Resource Library to access additional resources

Related Products

Important safety information

COMPOSITION

For PERIOLIMEL N4E, OLIMEL N5E, OLIMEL N7E, OLIMEL N9E and OLIMEL N12E:

Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Sodium acetate, trihydrate; Sodium glycerophosphate, hydrated; Potassium chloride; Magnesium chloride, hexahydrate; Calcium chloride, dehydrate; Glucose anhydrous.

For OLIMEL N7, OLIMEL N9 and OLIMEL N12:

Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Glucose anhydrous

Therapeutic indications

PERIOLIMEL / OLIMEL are indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

Contraindications

The use of PERIOLIMEL / OLIMEL with and without electrolytes are contra-indicated in the following situations:
-           In premature neonates, infants and children less than 2 years of age

-           Hypersensitivity to egg, soybean, or peanut proteins, or to any of the active substances or excipients

-           Congenital abnormalities of amino acid metabolism

-           Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by
            hypertriglyceridemia

-           Severe hyperglycemia

The use of PERIOLIMEL / OLIMEL with electrolytes are contra-indicated in the following situations:

-        Pathologically-elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.

Undesirable effects

System Organ Class

MedDRA Preferred Term

Frequency

Immune System Disorders

Hypersensitivity reactions including hyperhidrosis, pyrexia, chills, headache, skin rash (erythematous, papular, pustular, macular, generalised rash), pruritus, hot flush, dyspnoea

Not known

Cardiac Disorders

Tachycardia

Common

Metabolism and Nutrition Disorders

Decreased appetite

Common

 

Hypertriglyceridemia

Common

Gastrointestinal Disorders

Abdominal pain

Common

 

Diarrhea

Common

 

Nausea

Common

 

Vomiting

Not known

Vascular Disorders

Hypertension

Common

General disorders and administration site conditions

Extravasation which may result at infusion site level in: pain, irritation, swelling/oedema, erythema/warmth, skin necrosis, blisters/vesicles, inflammation, induration, skin tightness

Not known

The following class-like-adverse drug reactions (ADRs) have been described in other sources in relation to similar parenteral nutrition products; the frequency of these events is not known.

  • Blood and Lymphatic System Disorders: Thrombocytopenia
  • Hepatobiliary Disorders: Cholestasis, Hepatomegaly, Jaundice
  • Immune System Disorders: Hypersensitivity
  • Injury, poisoning and procedural complications: Parenteral nutrition associated liver disease
  • Investigations: Blood alkaline phosphatase increased, Transaminases increased, Blood bilirubin increased, Elevated liver enzymes
  • Renal and Urinary Disorders: Azotemia
  • Vascular disorders: Pulmonary vascular precipitates (pulmonary vascular embolism and respiratory distress)

Fat overload syndrome (very rare)

For a detailed posology, Special warnings and precautions, incompatibilities, interactions, pharmacological properties and pharmaceutical particulars, please refer to the full SPC.

Medicinal products are subject to medical prescription. Revision date: June 2020

Olimel N12 SmPC
Olimel N12E SmPC
PeriOlimel N4 & Olimel N5, N7, N9 SmPC